SCHEMBL66965

SCHEMBL66965

CC(C)(C)C(Cc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
CPA1 P15085 3/20 0.48
CPA3 P15088 3/20 0.48
FOLH1 Q04609 2/20 0.48
CPB1 P15086 1/20 0.48
CPB2 Q96IY4 1/20 0.48
POLB P06746 2/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTPN7 P35236 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15426321 1.00 CYP1A2 (0.55) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL20363221 0.86 ALPI (0.50) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL12650596 0.86 ALPI (0.50) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL1579881 0.85 SLC7A5 (0.55) SLC7A5CPA1FOLH1POLBBLM
SCHEMBL20394045 0.85 CYP1A2 (0.52) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL9692685 0.85 CYP1A2 (0.47) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL15426320 0.85 EPHX1 (0.53) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL1706267 0.85 MAPT (0.49) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL1703264 0.85 MAPT (0.49) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL14591098 0.85 EPHX1 (0.53) CYP1A2ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2023-06-15 US disclosed
US-20230043447-A1 PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2023-02-09 US disclosed
EP-4073242-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY Kumquat Biosciences Inc. (US) 2022-10-19 EP disclosed
CN-111601866-B Silicone adhesive composition, cured product, adhesive film, and adhesive tape 信越化学工业株式会社 2022-09-06 CN disclosed
US-20220202777-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. 2022-06-30 US disclosed
WO-2000051611-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-09-08 WO disclosed
US-6017385-A Ink compositions XEROX CORPORATION (US) 2000-01-25 US disclosed
US-5931995-A Ink compositions XEROX CORPORATION (US) 1999-08-03 US disclosed
EP-0403158-A2 Imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORPORATION (US) 1990-12-19 EP disclosed
US-4493842-A Fungicidal N-(phenyl-lower alkanoyl-)-imidazole derivatives, composition, and method of use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-01-15 US disclosed
EP-0095285-A1 N-acylimidazoles, their production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, STAMBP, TSPO CYP1A2 4092/4885ALPI 2630/4885PKM 51/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 CYP1A2 1066/4885ALPI 2037/4885PKM 2870/4885
US-20230043447-A1 PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES CD2BP2, DNPEP, LNPEP CYP1A2 4836/4885ALPI 3890/4885PKM 3804/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 CYP1A2 968/4885ALPI 2276/4885PKM 3579/4885
US-20220202777-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR3, FPR2 CYP1A2 4274/4885ALPI 4497/4885PKM 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.